Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI

Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, is the director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine (with tenure) at the Icahn School of Medicine at Mount Sinai in New York, NY.

After graduating as valedictorian from Boston Latin School, Dr Bhatt obtained his science degree as a National Merit Scholar from the Massachusetts Institute of Technology, his MD from Cornell University, his MPH from Harvard University, and his executive MBA from the University of Oxford. He trained in internal medicine at the University of Pennsylvania and in cardiology at Cleveland Clinic. He completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention and served as chief interventional fellow at Cleveland Clinic, where he spent many years as an interventional cardiologist, an associate professor of medicine, director of the interventional cardiology fellowship, associate director of the cardiovascular medicine fellowship, and associate director of the Cardiovascular Coordinating Center. He then served as chief of cardiology at VA Boston Healthcare System and, subsequently, as executive director of the Interventional Cardiovascular Program at Brigham and Women’s Hospital. He became a full professor of medicine at Harvard Medical School in 2012.

Dr Bhatt was a senior investigator for the TIMI Study Group. He was the principal investigator for the CHARISMA, CRESCENDO, COGENT, REDUCE-IT, SOLOIST, SCORED, and ENTRIGUE studies and co-principal investigator for the 3 CHAMPION trials, along with STAMPEDE, SAVOR-TIMI 53, SYMPLICITY HTN-3, THEMIS, THEMIS-PCI, and the REACH registry. In 2014, he was listed in the American Heart Association (AHA)/American Stroke Association Top Advances in Heart Disease and Stroke Research (for STAMPEDE and SYMPLICITY HTN-3); in 2018, REDUCE-IT was listed and also named the top cardiology trial byThe New England Journal of Medicine;in 2020 and again in 2021, SOLOIST and SCORED were listed by the AHA. He was the inaugural chair of the AHA's Get With The Guidelines Quality Oversight Committee, served as a trustee of the American College of Cardiology (ACC), and currently serves on the AHA Board of Directors for the New York City chapter.

Brigham and Women’s Hospital selected him as the 2014 Eugene Braunwald Scholar. He also received the Research Mentor Award from Brigham and Women’s Hospital Department of Medicine in 2016, the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s Hospital in 2017, the Distinguished Mentor Award from the ACC in 2018, the Distinguished Scientist Award from the AHA in 2019, the Honorary Lifetime Member of the NLA Award in 2021, and the Master Interventionalist of SCAI designation in 2022.

He has authored or coauthored more than 2000 publications and has been listed by Clarivate (previously known as the Web of Science Group) as a Highly Cited Researcher from 2014 to 2024. He is the editor ofCardiovascular Intervention: A Companion to Braunwald’s Heart Disease and Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease. He is also one of the coeditors of Braunwald’s Heart Disease. He previously served as senior associate editor for news and clinical trials for ACC.org and is the editor in chief of the Journal of Invasive Cardiology. He also served as editor in chief of the Harvard Heart Letter.